Global Rheumatoid Arthritis Drugs Market (2018-2022): Expected to Register a CAGR of ~8% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 6, 2018--The “Global Rheumatoid Arthritis Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.
The use of biologics and biosimilars for the treatment of RA is likely to help the market grow. Unlike synthetic DMARDs, biologics have targeted mechanisms of action and serve as promising molecules for the successful treatment of RA.
Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumatoid arthritis.
Social stigma associated with RA mainly due to physical deformities and functional limitations in RA patients. Various strategies are being adopted to tackle social stigma at the patient level.
Market TrendsHigh cost of RA drugs Use of biologics/biosimilars for treatment of RA Use of gene therapy for RA treatment Market dominance by TNF-alpha inhibitors Need for rheumatologists
Key PlayersAbbVie Amgen Johnson & Johnson Novartis Pfizer UCB Pharma
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 05: PIPELINE ANALYSISPipeline analysis
PART 06: MARKET SIZINGMarket definition Market sizing 2017 Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF MOLECULESegmentation by type of molecule Comparison by type of molecule Biologics - Market size and forecast 2017-2022 Small molecules - Market size and forecast 2017-2022 Market opportunity by type of molecule
PART 09: MARKET SEGMENTATION BY TYPE OF RASegmentation by type of RA Seropositive RA Seronegative RA
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPEGeographical segmentation Regional comparison Americas - Market size and forecast 2017-2022 EMEA - Market size and forecast 2017-2022 APAC - Market size and forecast 2017-2022 Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGESMarket drivers Market challenges
PART 14: MARKET TRENDSHigh cost of RA drugs Use of biologics/biosimilars for treatment of RA Use of gene therapy for RA treatment Market dominance by TNF-alpha inhibitors Need for rheumatologists
PART 15: VENDOR LANDSCAPEOverview Landscape disruption
PART 16: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors AbbVie Amgen Johnson & Johnson Novartis Pfizer UCB Pharma
For more information about this report visit https://www.researchandmarkets.com/research/bk8l6p/global_rheumatoid?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181206005826/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs,Musculoskeletal Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/06/2018 01:44 PM/DISC: 12/06/2018 01:44 PM